Cyclosporine A Drives a Th17- and Th2-Mediated Posttransplant Obliterative Airway Disease
Article first published online: 17 JAN 2013
© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 13, Issue 3, pages 611–620, March 2013
How to Cite
Lemaître, P. H., Vokaer, B., Charbonnier, L.-M., Iwakura, Y., Field, K. A., Estenne, M., Goldman, M., Leo, O., Remmelink, M. and Moine, A. L. (2013), Cyclosporine A Drives a Th17- and Th2-Mediated Posttransplant Obliterative Airway Disease. American Journal of Transplantation, 13: 611–620. doi: 10.1111/ajt.12067
- Issue published online: 25 FEB 2013
- Article first published online: 17 JAN 2013
- Manuscript Accepted: 17 NOV 2012
- Manuscript Revised: 16 NOV 2012
- Manuscript Received: 15 JUN 2012
- Walloon Region, the FNRS-Belgium and GlaxoSmithKline Biologicals
- Fonds Erasme
Disclaimer: Supplementary materials have been peer-reviewed but not copyedited.
Figure S1: Graft-infiltrating CD4± T cells are recipient derived.
Figure S2: B/C into B6 and B6 into B/C OAD are comparable.
Figure S3: CsA treatment prevents acute lesions of tracheal allografts at day 14.
Figure S4: CK14 counts in natives, syngeneic grafts and allografts.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.